** Shares of drug developer Arcus Biosciences RCUS.N rise 5.7% to $10.82
** Brokerage H.C. Wainwright upgrades rating on RCUS to "buy" from "neutral", raises PT to $24 from $18
** Brokerage sees opportunity for co's experimental drug casdatifan as second-line treatment for patients with a type of kidney cancer known as clear cell renal cell carcinoma
** Co is testing the drug as a monotherapy and in combination with other drugs
** Co to conduct a late-stage trial of casdatifan in combination with cancer drug cabozantinib as first- or second-line treatment in patients with the type of kidney cancer who have previously received treatment
** Co on Thursday posted Q4 revenue of $36 mln, beating analyst estimates of $28.9 mln, as per data compiled by LSEG
** Stock has fallen 47.9% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.